ARCH BIOPARTNERS INC
Long
Updated

Arch holding strong ahead of trial data.

56
With Trial data coming up the company is set for a bull run but in the meantime it has enough buyer interest to hold with strong support.
Note
Dragged down by bad macro. Still a good stock but the market conditions are just not ideal.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.